Incorporated in 1993, Syngene International Limited is an innovation-focussed global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world

Our state-of-the-art infrastructure, qualified team of scientists and rich expertise in emerging technologies enable us to improve research and development productivity, drive innovation and reduce time-to-market for novel molecules. Our competitive advantage stems from our ability to customise our scientific solutions.

This unique value proposition is reflected in our long-term partnerships with the world's leading pharmaceutical and biotechnology companies, along with strong relations with companies in other sectors and our growing association with small and virtual companies.

The business is divided into three units: Dedicated R&D Centres, Discovery Services and Development and Manufacturing Services.

Dedicated R&D Centres

Centres of excellence with dedicated infrastructure and scientific teams to suit the needs of individual clients.

Contracts are long-term in nature, usually five years or more and Fulltime- equivalent (FTE) engagements to support the client's R&D requirements.

Read more on this business unit

Discovery Services

Chemistry, biology, toxicology and bioinformatics services for both small and large molecules.

Undertaken for multiple clients, with the contracts being primarily FTE engagements and typically renewed annually.

Read more on this business unit

Development and Manufacturing Services

Pre-clinical studies, drug substance development, drug product development, allied services (stability services, viral testing, bioanalytical), clinical trials and manufacturing services for small molecules and biologics.

Largely Fee-for-service (FFS) engagements both for the short and long-term. Engagements generally expand in scope and extend in duration driven by our ability to generate added value for our clients.

Read more on this business unit

Syngene in Numbers*




Of the global top 10 Pharmaceutical companies


Qualified scientists

1.4 Mn sq. ft.

Area of R&D & manufacturing infrastructure


Long-term clients(collaborations extending over 5 years or more)


Share of sales from exports outside India

Quality Certifications

Our world-class facilities have received ISO 9001:2008, ISO 14001:2004, and OHSAS 18001:2007 certifications and have been audited by the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and major life sciences partners. Our animal health facilities are Good Laboratory Practice (GLP) certified by the Indian authorities and the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited.

Global Footprints

Headquartered in Bengaluru, India, Syngene is a global Contract Research Organisation (CRO). We have incorporated a wholly-owned overseas subsidiary in the United States (Syngene USA Inc.). This allows clients to have local access to our business development teams. We have also appointed regional business development representatives in the US (East and West Coast), Ireland and India. Our focus on client engagement has allowed us to build and maintain partnerships spanning the US, Europe, Asia-Pacific and Australia.

Geographic break-up of clients

(as on 31 March 2019)










Rest of world

Partnering with Diverse Industries





Animal health

Consumer goods

Speciality chemicals

Academic & non-profit organisations

Some of our Clients include:

Amgen Inc.

Artelo Biosciences

Baxter International Inc

Bristol-Myers Squibb



Merck KGaA

PharmAust Limited

Zumutor Biologics

Zoetis Inc.